387 related articles for article (PubMed ID: 22845482)
21. Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis.
Hamada T; Keum N; Nishihara R; Ogino S
J Gastroenterol; 2017 Mar; 52(3):265-275. PubMed ID: 27738762
[TBL] [Abstract][Full Text] [Related]
22. One microenvironment does not fit all: heterogeneity beyond cancer cells.
Kim IS; Zhang XH
Cancer Metastasis Rev; 2016 Dec; 35(4):601-629. PubMed ID: 27858305
[TBL] [Abstract][Full Text] [Related]
23. Tumoral heterogeneity of breast cancer.
Roulot A; Héquet D; Guinebretière JM; Vincent-Salomon A; Lerebours F; Dubot C; Rouzier R
Ann Biol Clin (Paris); 2016 Dec; 74(6):653-660. PubMed ID: 27848916
[TBL] [Abstract][Full Text] [Related]
24. The significance of intertumor and intratumor heterogeneity in liver cancer.
Liu J; Dang H; Wang XW
Exp Mol Med; 2018 Jan; 50(1):e416. PubMed ID: 29303512
[TBL] [Abstract][Full Text] [Related]
25. Consensus molecular subtypes (CMS) in metastatic colorectal cancer - personalized medicine decision.
Rebersek M
Radiol Oncol; 2020 May; 54(3):272-277. PubMed ID: 32463385
[TBL] [Abstract][Full Text] [Related]
26. A Practical Approach to Tumor Heterogeneity in Clinical Research and Diagnostics.
Stanta G; Bonin S
Pathobiology; 2018; 85(1-2):7-17. PubMed ID: 28750401
[TBL] [Abstract][Full Text] [Related]
27. Precision medicine and bladder cancer heterogeneity.
Ma G; Yang X; Liang Y; Wang L; Li D; Chen Y; Liang Z; Wang Y; Niu H
Bull Cancer; 2018 Oct; 105(10):925-931. PubMed ID: 30243478
[TBL] [Abstract][Full Text] [Related]
28. Decoding cancer heterogeneity: studying patient-specific signaling signatures towards personalized cancer therapy.
Flashner-Abramson E; Vasudevan S; Adejumobi IA; Sonnenblick A; Kravchenko-Balasha N
Theranostics; 2019; 9(18):5149-5165. PubMed ID: 31410207
[TBL] [Abstract][Full Text] [Related]
29. Conquering the challenges of genotypic and phenotypic tumor heterogeneity to realize the promise of personalized cancer therapy: the role of academia.
Merajver S; Phadke S; Soellner M
Trans Am Clin Climatol Assoc; 2017; 128():169-179. PubMed ID: 28790501
[TBL] [Abstract][Full Text] [Related]
30. Molecular epidemiology of cancer.
Chen YC; Hunter DJ
CA Cancer J Clin; 2005; 55(1):45-54; quiz 57. PubMed ID: 15661686
[TBL] [Abstract][Full Text] [Related]
31. Engineering Multidimensional Evolutionary Forces to Combat Cancer.
McCoach CE; Bivona TG
Cancer Discov; 2019 May; 9(5):587-604. PubMed ID: 30992280
[TBL] [Abstract][Full Text] [Related]
32. [Mutational tumor profiles beyond organ and tissue specificity: implications for diagnostics and clinical study design].
Klauschen F
Pathologe; 2014 Nov; 35 Suppl 2():277-80. PubMed ID: 25394977
[TBL] [Abstract][Full Text] [Related]
33. Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.
Ong FS; Das K; Wang J; Vakil H; Kuo JZ; Blackwell WL; Lim SW; Goodarzi MO; Bernstein KE; Rotter JI; Grody WW
Expert Rev Mol Diagn; 2012 Jul; 12(6):593-602. PubMed ID: 22845480
[TBL] [Abstract][Full Text] [Related]
34. The challenge of intratumour heterogeneity in precision medicine.
Seoane J; De Mattos-Arruda L
J Intern Med; 2014 Jul; 276(1):41-51. PubMed ID: 24661605
[TBL] [Abstract][Full Text] [Related]
35. Tumor Heterogeneity in Lymphomas: A Different Breed.
Schürch CM; Federmann B; Quintanilla-Martinez L; Fend F
Pathobiology; 2018; 85(1-2):130-145. PubMed ID: 28719907
[TBL] [Abstract][Full Text] [Related]
36. Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine.
Alvarez-Cubero MJ; Martinez-Gonzalez LJ; Robles-Fernandez I; Martinez-Herrera J; Garcia-Rodriguez G; Pascual-Geler M; Cozar JM; Lorente JA
Mol Diagn Ther; 2017 Apr; 21(2):167-178. PubMed ID: 27995550
[TBL] [Abstract][Full Text] [Related]
37. Variability in the Solid Cancer Cell Population and Its Consequences for Cancer Diagnostics and Treatment.
Brychtová V; Valík V; Vojtěšek B
Klin Onkol; 2018; 31(Suppl 2):5-13. PubMed ID: 31023018
[TBL] [Abstract][Full Text] [Related]
38. The multi-factorial nature of clinical multidrug resistance in cancer.
Assaraf YG; Brozovic A; Gonçalves AC; Jurkovicova D; Linē A; Machuqueiro M; Saponara S; Sarmento-Ribeiro AB; Xavier CPR; Vasconcelos MH
Drug Resist Updat; 2019 Sep; 46():100645. PubMed ID: 31585396
[TBL] [Abstract][Full Text] [Related]
39. Understanding the Cause and Consequence of Tumor Heterogeneity.
Khatib S; Pomyen Y; Dang H; Wang XW
Trends Cancer; 2020 Apr; 6(4):267-271. PubMed ID: 32209440
[TBL] [Abstract][Full Text] [Related]
40. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
